Verification evidence is still being completed.
PDF / print export
Antion Biosciences SA
Geneva, Switzerland
- Verified lead
- Marco Alessandrini
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering
- Review cycle
- 24 April 2026
- Full address
- Geneva, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- GlobeNewswire 2024 release naming Marco Alessandrini as CEO of Antion Biosciences.
- Editorial note
- Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering
University of Geneva spin-off, Public CEO disclosure via GlobeNewswire, Swiss Biotech Association listing
Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Geneva, Switzerland
Antion Biosciences SA
Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering · Preclinical cell-therapy development
Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
- Lead
- Marco Alessandrini (verified ↗)
- Address
- Geneva, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical cell-therapy development
- Capabilities
- Multiplex miRNA Gene Silencing Platform · Allogeneic CAR-T Development · Cell and Gene Engineering
- Founded
- 2018
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Marco Alessandrini
Chief Executive Officer
Full addressGeneva, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Preclinical cell-therapy development
Geneva, Switzerland. Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for future clinical development
University of Geneva spin-off, Public CEO disclosure via GlobeNewswire, Swiss Biotech Association listing
Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering
Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
Editorial note
Antion Biosciences is a University of Geneva spin-off (founded 2016) with a named CEO and a proprietary multiplex miRNA gene-silencing platform supporting the miCAR7 allogeneic CAR-T lead.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Multiplex miRNA Gene Silencing Platform
Allogeneic CAR-T Development
Cell and Gene Engineering
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
miRNA gene-silencing platform
CAR-T cell engineering workflow
Preclinical in vivo models
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Antion Biosciences SA located?
- Antion Biosciences SA operates from Geneva, Switzerland, Geneva, Switzerland.
- Who runs Antion Biosciences SA?
- Antion Biosciences SA is led by Marco Alessandrini, Chief Executive Officer. Verified 24 Apr 2026.
- What does Antion Biosciences SA do?
- Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform. Core capabilities: Multiplex miRNA Gene Silencing Platform, Allogeneic CAR-T Development, Cell and Gene Engineering.
Editorial context
Related technical briefs
Briefs that name Geneva as a covered market or city.